BlossomHill Therapeutics Management

Management criteria checks 2/4

BlossomHill Therapeutics' CEO is Jingrong Jean Cui, appointed in Jun 2020, has a tenure of 6.17 years. total yearly compensation is $763.95K, comprised of 65.4% salary and 34.6% bonuses, including company stock and options. directly owns 3.48% of the company’s shares, worth $17.27M. The average tenure of the management team and the board of directors is 1.6 years and 5.5 years respectively.

Key information

Jingrong Jean Cui

Chief executive officer

US$763.9k

Total compensation

CEO salary percentage	65.45%
CEO tenure	6.2yrs
CEO ownership	3.5%
Management average tenure	1.6yrs
Board average tenure	5.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jingrong Jean Cui's remuneration changed compared to BlossomHill Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2026	n/a	n/a	-US$71m
Dec 31 2025	US$764k	US$500k	-US$61m

Compensation vs Market: Jingrong's total compensation ($USD763.95K) is below average for companies of similar size in the US market ($USD2.41M).

Compensation vs Earnings: Insufficient data to compare Jingrong's compensation with company performance.

CEO

Jingrong Jean Cui (63 yo)

6.2yrs

Tenure

US$763,947

Compensation

Dr. Jingrong Jean Cui, Ph D, is Scientific Founder, President, CEO & Director of BlossomHill Therapeutics, Inc. since June 2020. Dr. Cui is a renowned oncology drug designer who is the lead inventor of mul...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Li Yishan	Co-Founder & Executive Chairman	6.2yrs	US$574.00k	0.41% $ 2.0m
Jingrong Jean Cui	Scientific Founder	6.2yrs	US$763.95k	3.48% $ 17.3m
Jason Keyes	CFO & Executive VP	1.3yrs	US$1.27m	0.0023% $ 11.3k
Geoff Oxnard	Chief Medical Officer & Executive VP	1.6yrs	US$1.65m	0.058% $ 287.8k
Vincent Liptak	General Counsel & Executive VP	3.3yrs	no data	0.36% $ 1.8m
Zachary Zimmerman	Senior Vice President of Clinical Development	no data	no data	no data
Eugene Rui	Senior Vice President of Chemistry	no data	no data	no data
Z. Shao	Senior Vice President of CMC	no data	no data	no data
Ashley Preston	Senior VP and Head of Regulatory Affairs & Quality Assurance	1.6yrs	no data	no data
Antonio Garrido-Montalban	Senior Vice President of Drug Substance	1.6yrs	no data	no data
Diane Wang	Senior Vice President of Clinical Pharmacology & Preclinical Development	1.6yrs	no data	no data
Jill Smith	Senior Vice President of Clinical Operations & Project Management	1.6yrs	no data	no data

1.6yrs

Average Tenure

55yo

Average Age

Experienced Management: BLSM's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Li Yishan	Co-Founder & Executive Chairman	6.2yrs	US$574.00k	0.41% $ 2.0m
Jingrong Jean Cui	Scientific Founder	6.2yrs	US$763.95k	3.48% $ 17.3m
Carl Gordon	Independent Director	5.5yrs	no data	no data
John Schmid	Independent Director	less than a year	no data	0.020% $ 97.1k
Sheila Gujrathi	Lead Independent Director	less than a year	no data	0.29% $ 1.5m
Bihua Chen	Independent Director	5.5yrs	no data	no data
Sundeep Agrawal	Independent Director	2.7yrs	US$46.44k	0% $ 0

5.5yrs

Average Tenure

61yo

Average Age

Experienced Board: BLSM's board of directors are considered experienced (5.5 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/08/16 02:30
End of Day Share Price	2026/08/14 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BlossomHill Therapeutics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.